Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empasiprubart SC vs IV in Healthy Adult Participants
NCT07612020Phase 1Recruiting
- Sponsor
- argenx
- Start
- Mar 2026
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of empasiprubart (5 arms), sponsored by argenx. Primary endpoints: Absolute Bioavailability via abdomen as assessed by AUC0-inf SC versus AUC0-inf IV at 33 weeks, Absolute Bioavailability via thigh as assessed by AUC0-inf SC versus AUC0-inf IV at 33 weeks and 1 more. Started Mar 2026; status: recruiting.
02
Drugs
empasiprubart
Beyond the preview
Go deeper on NCT07612020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07612020.